Effect of heat-shock protein-90 (HSP90) inhibition on human hepatocytes and on liver regeneration in experimental models

Surgery

Volumn 147, Issue 5, 2010, Pages 704-712

  Hackl, Christina ^a   Mori, Akira ^a   Moser, Christian ^a   Lang, Sven A ^a   Dayoub, Rania ^a   Weiss, Thomas S ^a   Schlitt, Hans J ^a   Geissler, Edward K ^a   Hellerbrand, Claus ^b   Stoeltzing, Oliver ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CARBON TETRACHLORIDE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SCATTER FACTOR; STAT3 PROTEIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL MOUSE; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER INJURY; LIVER REGENERATION; LIVER RESECTION; MALE; MOUSE; NONHUMAN; PARTIAL HEPATECTOMY; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STAINING; UPREGULATION;

ACUTE DISEASE; ANIMALS; CARBON TETRACHLORIDE; CELLS, CULTURED; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; HEPATECTOMY; HEPATOCYTE GROWTH FACTOR; HEPATOCYTES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIVER NEOPLASMS; LIVER REGENERATION; MALE; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950857856     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2009.10.061     Document Type: Article

References (40)

1. Gruenberger B., Tamandl D., Schueller J., Scheithauer W., Zielinski C., Herbst F., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26 (2008) 1830-1835
2. Nordlinger B., Sorbye H., Glimelius B., Poston G.J., Schlag P.M., Rougier P., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008) 1007-1016
3. Vauthey J.N., Zorzi D., and Pawlik T.M. Making unresectable hepatic colorectal metastases resectable-does it work?. Semin Oncol 32 6 Suppl. 9 (2005) S118-S122
4. Aussilhou B., Dokmak S., Faivre S., Paradis V., Vilgrain V., and Belghiti J. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 16 (2009) 1553-1559
5. Kesmodel S.B., Ellis L.M., Lin E., Chang G.J., Abdalla E.K., Kopetz S., et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26 (2008) 5254-5260
6. Morris-Stiff G., Tan Y.M., and Vauthey J.N. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol 34 (2008) 609-614
7. Parikh A.A., Gentner B., Wu T.T., Curley S.A., Ellis L.M., and Vauthey J.N. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 7 (2003) 1082-1088
8. Stoeltzing O., Liu W., Reinmuth N., Parikh A., Ahmad S.A., Jung Y.D., et al. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol 10 (2003) 722-733
9. Barginear M.F., Van Poznak C., Rosen N., Modi S., Hudis C.A., and Budman D.R. The heat shock protein 90 chaperone complex: an evolving therapeutic target. Curr Cancer Drug Targets 8 (2008) 522-532
10. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62 (2002) 2478-2482
11. Moser C., Lang S.A., Kainz S., Gaumann A., Fichtner-Feigl S., Koehl G.E., et al. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther 6 (2007) 2868-2878
12. Zhang H., and Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82 (2004) 488-499
13. Isaacs J.S., Xu W., and Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3 (2003) 213-217
14. Neckers L., and Ivy S.P. Heat shock protein 90. Curr Opin Oncol 15 (2003) 419-424
15. Kaur G., Belotti D., Burger A.M., Fisher-Nielson K., Borsotti P., Riccardi E., et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 10 (2004) 4813-4821
16. Sanderson S., Valenti M., Gowan S., Patterson L., Ahmad Z., Workman P., et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 5 (2006) 522-532
17. Goetz M.P., Toft D., Reid J., Ames M., Stensgard B., Safgren S., et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23 (2005) 1078-1087
18. Ramanathan R.K., Egorin M.J., Eiseman J.L., Ramalingam S., Friedland D., Agarwala S.S., et al. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 13 (2007) 1769-1774
19. Solit D.B., Osman I., Polsky D., Panageas K.S., Daud A., Goydos J.S., et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14 (2008) 8302-8307
20. Shi Q., Dong Z., and Wei H. The involvement of heat shock proteins in murine liver regeneration. Cell Mol Immunol 4 (2007) 53-57
21. Jiang W.G., Hallett M.B., and Puntis M.C. Hepatocyte growth factor/scatter factor, liver regeneration and cancer metastasis. Br J Surg 80 (1993) 1368-1373
22. Reynaert H., Chavez M., and Geerts A. Vascular endothelial growth factor and liver regeneration. J Hepatol 34 (2001) 759-761
23. Thasler W.E., Weiss T.S., Schillhorn K., Stoll P.T., Irrgang B., and Jauch K.W. Charitable state-controlled foundation human tissue and cell research: ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank 4 (2003) 49-56
24. Thasler W.E., Dayoub R., Muhlbauer M., Hellerbrand C., Singer T., Grabe A., et al. Repression of cytochrome P450 activity in human hepatocytes in vitro by a novel hepatotrophic factor, augmenter of liver regeneration. J Pharmacol Exp Ther 316 (2006) 822-829
25. Weiss T.S., Pahernik S., Scheruebl I., Jauch K.W., and Thasler W.E. Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid. J Hepatol 38 (2003) 476-482
26. Lang S.A., Moser C., Gaumann A., Klein D., Glockzin G., Popp F.C., et al. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13 (2007) 6459-6468
27. Nikfarjam M., Malcontenti-Wilson C., Fanartzis M., Daruwalla J., and Christophi C. A model of partial hepatectomy in mice. J Invest Surg 17 (2004) 291-294
28. Lang S.A., Klein D., Moser C., Gaumann A., Glockzin G., Dahlke M.H., et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 6 (2007) 1123-1132
29. Lang S.A., Moser C., Fichnter-Feigl S., Schachtschneider P., Hellerbrand C., Schmitz V., et al. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 49 (2009) 523-532
30. Powers M.V., Clarke P.A., and Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14 (2008) 250-262
31. Hellerbrand C., Stefanovic B., Giordano F., Burchardt E.R., and Brenner D.A. The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol 30 (1999) 77-87
32. Guo F., Rocha K., Bali P., Pranpat M., Fiskus W., Boyapalle S., et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 65 (2005) 10536-10544
33. Shu C.W., Cheng N.L., Chang W.M., Tseng T.L., and Lai Y.K. Transactivation of hsp70-1/2 in geldanamycin-treated human non-small cell lung cancer H460 cells: involvement of intracellular calcium and protein kinase C. J Cell Biochem 94 (2005) 1199-1209
34. Gao C.F., Zhou F.G., Wang H., Huang Y.F., Ji Q., and Chen J. Genetic recombinant expression and characterization of human augmenter of liver regeneration. Dig Dis Sci 54 (2009) 530-537
35. Tanigawa K., Sakaida I., Masuhara M., Hagiya M., and Okita K. Augmenter of liver regeneration (ALR) may promote liver regeneration by reducing natural killer (NK) cell activity in human liver diseases. J Gastroenterol 35 (2000) 112-119
36. Thasler W.E., Schlott T., Thelen P., Hellerbrand C., Bataille F., Lichtenauer M., et al. Expression of augmenter of liver regeneration (ALR) in human liver cirrhosis and carcinoma. Histopathology 47 (2005) 57-66
37. Haber B.A., Mohn K.L., Diamond R.H., and Taub R. Induction patterns of 70 genes during nine days after hepatectomy define the temporal course of liver regeneration. J Clin Invest 91 (1993) 1319-1326
38. Fausto N., Campbell J.S., and Riehle K.J. Liver regeneration. Hepatology 43 2 Suppl 1 (2006) S45-S53
39. Bard-Chapeau E.A., Yuan J., Droin N., Long S., Zhang E.E., Nguyen T.V., et al. Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection. Mol Cell Biol 26 (2006) 4664-4674
40. Khetani S.R., and Bhatia S.N. Microscale culture of human liver cells for drug development. Nat Biotechnol 26 (2008) 120-126